GLP-1 Medicines and Addiction: Could the Same Brain Pathway Behind Food Noise Affect Alcohol Cravings?
What if the medication changing the conversation around weight loss could also change the conversation around addiction?
GLP-1 medicines such as semaglutide have become a major health trend, with terms like "food noise," "cravings" and "appetite regulation" entering everyday conversations.
Now, researchers are investigating whether their effects extend beyond eating behaviour to the brain’s reward pathways involved in addiction.
GLP-1 receptor agonists mimic the naturally occurring hormone glucagon-like peptide-1. They increase glucose-dependent insulin release, reduce glucagon secretion, slow gastric emptying and increase satiety. GLP-1 receptors are also found in brain regions involved in reward, motivation and appetite. Researchers propose that GLP-1 signalling may influence craving, reward processing, stress responses and alcohol-related reinforcement.
The precise mechanism in addiction remains under investigation.
The emerging evidence is intriguing. A 2025 randomised trial found that low-dose semaglutide reduced alcohol craving and drinks consumed per drinking occasion.
A 2026 randomised trial involving people with alcohol use disorder and obesity found greater reductions in heavy-drinking days when semaglutide was combined with cognitive behavioural therapy.
The potential upsides
• Reduced alcohol craving and consumption in emerging research
• Appetite and food-intake regulation
• Potential effects on reward pathways
• Significant weight reduction for appropriate clinical candidates
• Potential metabolic health benefits.
The reality check
GLP-1 medicines can bring gastrointestinal symptoms including nausea, vomiting, diarrhoea and constipation.
Rapid weight loss can also involve loss of lean mass, making protein, resistance training and adequate nutrition important considerations.
Body changes can be surprisingly visible too. Some people notice changes in their face, arms or even the appearance of their hands as body fat and fluid levels change. Research specifically examining hand appearance remains limited.
Importantly, GLP-1 medicines are an emerging area of addiction research, rather than an established stand-alone treatment for addiction.
Recovery is bigger than one medication
Medication may become one tool in a much larger recovery toolkit.
Nutrition feeds the brain. Exercise supports physical and psychological wellbeing. Mindfulness can help people recognise cravings without automatically acting on them. Sleep, connection, therapy and meaningful routines help build the foundations for sustainable change.
The future of addiction treatment may involve looking beyond a single substance or behaviour and asking a bigger question:
What is happening inside the brain—and how can the whole person be supported to recover?
GLP-1 research is opening an exciting new chapter. The science is still developing, but one thing is becoming increasingly clear:
Addiction recovery is not simply about willpower. It is about biology, psychology, environment, behaviour—and potentially, the brain’s reward system itself.
References:
Klausen, M. K., et al. (2026). Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: A randomised, double-blind, placebo-controlled trial. The Lancet.
Hendershot, C. S., et al. (2025). Once-weekly semaglutide in adults with alcohol use disorder: A randomized clinical trial. JAMA Psychiatry, 82(4), 395–405.
Patel, S., Blaney, H., Nassar, S., & Singal, A. K. (2025). GLP-1 receptor agonists and alcohol use disorder: A systematic review. Alcohol and Alcoholism, 61(1), agaf069.
Petrie, G. N., & Mayo, L. M. (2025). GLP-1 receptor agonists for the treatment of alcohol use disorder. Journal of Clinical Investigation, 135(9), e192414.
Rosen, C. J., & Ingelfinger, J. R. (2026). GLP-1 receptor agonists. New England Journal of Medicine, 394, 1313–1324.
McGowan, B. M., et al. (2023). Impact of BMI and comorbidities on efficacy of once-weekly semaglutide: Post hoc analyses of the STEP 1 randomized trial. Obesity.
Li, J., Zhou, Z., Gao, G., & Zang, L. (2024). Effectiveness of exercise intervention in improving physical and mental status of patients with alcohol use disorders: A systematic review and meta-analysis. PLOS ONE.
Li, W., Howard, M. O., Garland, E. L., McGovern, P., & Lazar, M. (2017). Mindfulness treatment for substance misuse: A systematic review and meta-analysis. Journal of Substance Abuse Treatment, 75, 62–96.
Neeland, I. J., et al. (2024). Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes, Obesity and Metabolism.
Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis. (2025). Metabolism, 164, 156113.
Effects of glucagon-like peptide-1 receptor agonists on alcohol consumption: A systematic review and meta-analysis. (2025). eClinicalMedicine.
Nutritional and lifestyle supportive care recommendations for management of obesity with GLP-1-based therapies: An expert consensus statement using a modified Delphi approach. (2025).
Comments